For research use only. Not Intended for Therapeutic Use!
|Target:||target: HSP90 |
|We match the lowest price on market.|
Debio 0932 ( CUDC-305 ) is a novel heat shock protein 90 (HSP90) inhibitor trong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L). 
in vitro: H1993 and H1975 NSCLC cells were incubated with 1 μmol/L CUDC-305 for 7 hours and then cultured in compound-free medium for an additional 0, 17, or 24 hours, respectively, before being analyzed by Western blot 
in vivo: CUDC-305 was delivered through oral gavage on an every-other-day (once every two days) dosing schedule at various doses up to 160 mg/kg-its maximum tolerated dose in nude mice. In survival studies in Balb/C nude mice, the highest dose was reduced to 120 mg/kg as a result of the compromised animal condition due to lung and brain tumor implantation surgeries.